Voyager Therapeutics Financial Results
Voyager Therapeutics reported third quarter 2026 financial results, ending the period with $132 million in cash and extending its projected runway into Q2 2028. The company highlighted progress in its Alzheimer’s disease pipeline, with clinical data readouts for VY7523 expected in Q4 2026 and patient dosing for VY1706 anticipated in the coming months.
“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months.”
Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager
“During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”
Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager